This grant is for establishing a major, goal-driven Consortium comprised of exceptional institutions and investigators. Its core purpose is to significantly accelerate the clinical translation of foundational Gulf War Illness (GWI) research, moving discoveries into practical clinical therapies. The ultimate aim is to decrease the profound impact of this illness on affected individuals. The Consortium’s specific objectives include conceiving, designing, developing, and rigorously conducting collaborative Phase I and/or II clinical trials. These trials will evaluate promising therapeutic agents, focusing on their efficacy for the comprehensive management or effective treatment of Gulf War Illness, thereby fostering innovative solutions for patient care.
Opportunity ID: 293982
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-17-GWIRP-CCA |
| Funding Opportunity Title: | DoD Gulf War Illness, Clinical Consortium Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 19, 2017 |
| Last Updated Date: | Sep 15, 2017 |
| Original Closing Date for Applications: | Sep 21, 2017 |
| Current Closing Date for Applications: | Sep 28, 2017 |
| Archive Date: | Oct 28, 2017 |
| Estimated Total Program Funding: | $8,000,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The GWIRP Clinical Consortium Award mechanism is being offered for the first time in FY17. The FY17 GWIRP Clinical Consortium Award is intended to support a major goal-/product-driven Consortium of exceptional institutions and investigators that will accelerate the clinical translation of basic GWI research into clinical therapies and ultimately decrease the impact of the illness. The objectives of the Consortium shall be to conceive, design, develop, and conduct collaborative Phase I and/or II clinical trials of promising therapeutic agents for the management or treatment of GWI. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| The CDMRP and USAMRMC realize that hurricanes Harvey and Irma may cause problems for grant applicants in the impacted areas. This Program Announcement has been modified to extend the application submission deadline. | Sep 15, 2017 | |
| Sep 15, 2017 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-17-GWIRP-CCA |
| Funding Opportunity Title: | DoD Gulf War Illness, Clinical Consortium Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 19, 2017 |
| Last Updated Date: | Sep 15, 2017 |
| Original Closing Date for Applications: | Sep 21, 2017 |
| Current Closing Date for Applications: | Sep 28, 2017 |
| Archive Date: | Oct 28, 2017 |
| Estimated Total Program Funding: | $8,000,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The GWIRP Clinical Consortium Award mechanism is being offered for the first time in FY17. The FY17 GWIRP Clinical Consortium Award is intended to support a major goal-/product-driven Consortium of exceptional institutions and investigators that will accelerate the clinical translation of basic GWI research into clinical therapies and ultimately decrease the impact of the illness. The objectives of the Consortium shall be to conceive, design, develop, and conduct collaborative Phase I and/or II clinical trials of promising therapeutic agents for the management or treatment of GWI. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-17-GWIRP-CCA |
| Funding Opportunity Title: | DoD Gulf War Illness, Clinical Consortium Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 15, 2017 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 21, 2017 |
| Archive Date: | Oct 21, 2017 |
| Estimated Total Program Funding: | $8,000,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The GWIRP Clinical Consortium Award mechanism is being offered for the first time in FY17. The FY17 GWIRP Clinical Consortium Award is intended to support a major goal-/product-driven Consortium of exceptional institutions and investigators that will accelerate the clinical translation of basic GWI research into clinical therapies and ultimately decrease the impact of the illness. The objectives of the Consortium shall be to conceive, design, develop, and conduct collaborative Phase I and/or II clinical trials of promising therapeutic agents for the management or treatment of GWI. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Related Documents
Folder 293982 Full Announcement-FY17 GWIRP CCA -> GWIRP_FY17 CCA PA_GG.PDF
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00232650 | May 19, 2017 | Sep 28, 2017 | View |
Package 1
Mandatory forms
293982 RR_SF424_2_0-2.0.pdf
293982 RR_Budget_1_4-1.4.pdf
293982 RR_KeyPersonExpanded_2_0-2.0.pdf
293982 PerformanceSite_2_0-2.0.pdf
293982 AttachmentForm_1_2-1.2.pdf
Optional forms
293982 RR_SubawardBudget30_1_4-1.4.pdf